Popular Articles

St. Jude Medical Announces Australian TGA Regulatory Approval For Libra Deep Brain Stimulation Systems For Parkinson's Disease
St. Jude Medical, Inc. (NYSE:STJ) announced Australian Therapeutic Goods Administration (TGA) approval of its Libra® and LibraXP™ deep brain stimulation (DBS) systems for treating the symptoms of Parkinson"s disease, a neurological disorder that progressively diminishes a person"s control over his or her movements.
generic viagra online
FDA: New Public Health Regulation To Improve Egg Safety And Reduce Salmonella Illnesses
The U.S. Food and Drug Administration announced a regulation expected to prevent each year 79,000 cases of foodborne illness and 30 deaths caused by consumption of eggs contaminated with the bacterium Salmonella enteritidis.
News of the day
Boston Scientific Begins Clinical Trial For Next-Generation Nitinol Stent To Treat Iliac Artery Disease
Boston Scientific Corporation (NYSE: BSX) announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company"s EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease that impacts a patient"s lower extremities. The first U.S. patient was enrolled on May 14 by Nicolas W. Shammas, M.D., at Trinity Terrace Park Hospital in Bettendorf, Iowa.
Public Health

454 Technology Applied To Closing The Gaps In The Human Genome

Sequence gaps in human chromosome 15 have been closed by the application of 454 technology. Researchers writing in BioMed Central"s open access journal Genome Biology have described a simple and scalable method for finishing non-structural gaps in genome assemblies. Manuel Garber worked with a team of researchers from the Broad Institute of MIT and Harvard, Massachusetts, USA, to develop an approach for closing class III gaps, those non-structural gaps that are refractory to clone-based approaches, using 454 sequencing. He said, "While clone-based methods remain an effective means of attacking structural gaps, they will not resolve gaps that arise from sequences recalcitrant to bacterial cloning. The human genome still contains 127 class III gaps, many of which are likely to be closable by the method described here". A key difference between the 454 methodology and traditional sequencing is that the 454 process has no bacterial cloning step. Garber and his colleagues designed six primer pairs anchored in unique sequences that tiled the three gaps and used PCR to amplify these regions. They then sheared and directly sequenced the gap-spanning PCR products, using the 454 Life Sciences GS FLX. For each gap, the 454 reads were successfully assembled into a single, high-quality contig spanning the gap region. Garber said, "The technique we present could be also be applied to the targeted closure of gaps in other finished or near finished genomes such as mouse and dog, which contain 103 and 47 class III gaps, respectively". Closing gaps in the human genome using sequencing by synthesis Manuel Garber, Michael C Zody, Harindra M Arachchi, Aaron Berlin, Sante Gnerre, Lisa M Green, Niall Lennon and Chad Nusbaum Genome Biology "in press" http://genomebiology.com/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):